PsoProtect Registry Partnership

PSOPROTECT IS AN INTERNATIONAL REGISTRY FOR HEALTH CARE PROVIDERS TO REPORT OUTCOMES OF COVID-19 IN INDIVIDUALS WITH PSORIASIS.

Project Description

PsoProtect is an international registry developed to enable clinicians to report outcomes of COVID-19 in individuals with psoriasis. It is hoped that PsoProtect will help us to understand how immunomodulator therapies and comorbidities impact outcomes to COVID-19 in psoriasis and it will provide real-time updates on cases reported for the benefit of the dermatology community. PsoProtect seeks to improve our understanding of how factors such as immunomodulator therapies and comorbidities impact outcomes to COVID-19 in psoriasis.

IPC is pleased to be part of this important initiative and asks if you have a psoriasis patient diagnosed with COVID-19, please contribute to this important registry by submitting your case using the online PsoProtect case report form.

In addition, an adjoining registry PsoProtectMe has been set up for patients to self-report their experiences.

Project Leaders


Dr. Satveer Mahil, UK	Prof. Catherine Smith, UK

Publications

Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study

Satveer K. Mahil, Nick Dand, Kayleigh J. Mason, Zenas ZN. Yiu, Teresa Tsakok, Freya Meynell, Bola Coker, Helen McAteer, Lucy Moorhead, Teena Mackenzie, Maria Teresa Rossi, Raquel Rivera, Emmanuel Mahe, Andrea Carugno, Michela Magnano, Giulia Rech, Esther A. Balogh, Steven R. Feldman, Claudia De La Cruz, Siew Eng Choon, Luigi Naldi, Jo Lambert, Phyllis Spuls, Denis Jullien, Hervé Bachelez, Devon E. McMahon, Esther E. Freeman, Paolo Gisondi, Luis Puig, Richard B. Warren, Paola Di Meglio, Sinéad M. Langan, Francesca Capon, Christopher EM. Griffiths, Jonathan N. Barker, Catherine H. Smith. J Allergy Clin Immunol. 2020 Oct 16; S0091-6749(20)31413-5. doi: 10.1016/j.jaci.2020.10.007. [Epub ahead of print]

Background
The multi-morbid burden and use of systemic immunosuppressants in people with psoriasis may confer greater risk of adverse COVID-19 outcomes but data are limited.

Objective
Characterize the course of COVID-19 in psoriasis and identify factors associated with hospitalization.

Methods
Clinicians reported psoriasis patients with confirmed/suspected COVID-19 via an international registry, PsoProtect. Multiple logistic regression assessed the association between clinical/demographic characteristics and hospitalization. A separate patient-facing registry characterized risk-mitigating behaviours.

Results
Of 374 clinician-reported patients from 25 countries, 71% were receiving a biologic, 18% a non-biologic and 10% no systemic treatment for psoriasis. 348 (93%) fully recovered from COVID-19, 77 (21%) were hospitalized and nine (2%) died. Increased hospitalization risk was associated with older age (multivariable-adjusted OR 1.59 per 10 years, 95% CI 1.19-2.13), male sex (OR 2.51, 95% CI 1.23-5.12), non-white ethnicity (OR 3.15, 95% CI 1.24-8.03) and comorbid chronic lung disease (OR 3.87, 95% CI 1.52-9.83). Hospitalization was more frequent in patients using non-biologic systemic therapy than biologics (OR 2.84, 95% CI 1.31-6.18). No significant differences were found between biologic classes. Independent patient-reported data (n=1,626 across 48 countries) suggested lower levels of social isolation in individuals receiving non-biologic systemic therapy compared to biologics (OR 0.68, 95% CI 0.50-0.94).

Conclusion
In this international moderate-severe psoriasis case series, biologics use was associated with lower risk of COVID-19-related hospitalization than non-biologic systemic therapies, however further investigation is warranted due to potential selection bias and unmeasured confounding. Established risk factors (being older, male, non-white ethnicity, comorbidities) were associated with higher hospitalization rates.

Clinical implications
We identify risk factors for COVID-19-related hospitalization in psoriasis patients, including older age, male sex, non-white ethnicity and comorbidities. Use of biologics was associated with lower hospitalization risk than non-biologic systemic therapies.

Keywords
COVID-19; biologics; hospitalization; immunosuppressants; psoriasis; risk factors.

Link to PubMed.

Project Results

View current data

View summary data from the first 200 cases

View summary data from the first 50 cases

WATCH NOW
Catherine Smith, MD, and Savteer Mahil, MD, talk to IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD, about their goals for the PsoProtect patient registry to study COVID-19 and psoriasis.

Latest news

Commentary: NPF COVID-19 Task Force Guidance Statements

January 06, 2021

Recently, the Task Force (TF) of the National Psoriasis Foundation (NPF) released a revised version of its COVID-19 statement after an in-depth analysis of publicly available data with two currently approved anti-SARS-CoV-2 vaccines in the US, both mRNA-based.

IPC Statement on SARS-CoV-2 Vaccines and Psoriasis

December 02, 2020

While the news of a potential SARS-CoV-2 vaccine is to be welcomed, the impact of psoriasis therapy, particularly systemic therapy, on the effectiveness and safety of vaccines needs to be considered.

Psoriasis updates in a nutshell: Pathogenesis, markers and therapeutics

November 19, 2020

Get the latest updates about psoriasis on topics such as pathogenesis, markers and therapeutics from Dr. Mohamed El-Komy in this short IPC video.

Are you a dermatologist practicing in the Middle East?

November 03, 2020

Get the latest news on treating psoriasis in the Middle East with Dr. El Sayed.

More News

Psoriasis News

the latest news from ipc, industry and others

PsoProtect Registry Partnership

PSOPROTECT IS AN INTERNATIONAL REGISTRY FOR HEALTH CARE PROVIDERS TO REPORT OUTCOMES OF COVID-19 IN INDIVIDUALS WITH PSORIASIS.

Project Description

Project Leaders

Publications

Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study

Project Results

WATCH NOW
Catherine Smith, MD, and Savteer Mahil, MD, talk to IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD, about their goals for the PsoProtect patient registry to study COVID-19 and psoriasis.

Latest news

Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

PsoProtect Registry Partnership

PSOPROTECT IS AN INTERNATIONAL REGISTRY FOR HEALTH CARE PROVIDERS TO REPORT OUTCOMES OF COVID-19 IN INDIVIDUALS WITH PSORIASIS.

Project Description

Project Leaders

Publications

Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study

Project Results

WATCH NOW Catherine Smith, MD, and Savteer Mahil, MD, talk to IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD, about their goals for the PsoProtect patient registry to study COVID-19 and psoriasis.

Latest news

Advancing Knowledge. Enhancing Care.

WATCH NOW
Catherine Smith, MD, and Savteer Mahil, MD, talk to IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD, about their goals for the PsoProtect patient registry to study COVID-19 and psoriasis.